focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Cello Group Sees 2013 Profit Increase

Thu, 20th Mar 2014 12:49

LONDON (Alliance News) - Cello Group PLC Thursday reported an increase in profit and revenue for the full-year, reflecting a strong performance across the business.

The marketing consultancy group posted pretax profit of GBP5.5 million for 2013, up from GBP1.4 million, as revenue rose 18.2% to GBP159.7 million, from GBP135.1 million a year earlier.

Cello has two operating divisions, Cello Health and Cello Signal previously Cello Consumer which both performed strongly during the year.

Cello Health, which serves the pharmaceutical industry, saw gross profit rise to GBP35.6 million, from GBP31.3 million. The company won a number of clients during the year including technology firm Sony and NHS Blood Transfusions in the UK. Despite an ongoing senior headcount increase, operating margin increased slightly to 21.2% from 20.8%.

Cello Signal, which advises marketing clients, saw gross profit climb to GBP37.9 million from GBP32.7 million. It also won a number of new clients including Walt Disney and the British Red Cross. Operating margin rose to 10.2% from 9.1%.

Overall, the firm said the 2013 improvement has been underpinned by robust like-for-like gross profit growth of 11.4%.

"This growth has been achieved across the whole business and notably in Cello Signal, where growing digital gross profit and gross profit from technically related services was supplemented by the impact of a significant incremental project," it said.

The growth has also been assisted by the GBP2.1 million acquisition of Mash Health Ltd in January last year. Mash provides consultancy and communication services to a wide portfolio of pharmaceutical, nutraceutical and consumer healthcare clients.

Cello said it is pleased with the performance of the Mash business so far.

Financial net debt fell almost 60% to GBP3.6 million from GBP8.7 million, said the company, which increased its full-year dividend 12.5% to 2.25 pence from 2.00 pence.

The stock was trading at 86.00 pence, down 1.00 pence or 1.2%.

By Anthony Tshibangu; anthonytshibangu@alliancenews.com; @AnthonyAllNews

Copyright © 2014 Alliance News Limited. All Rights Reserved.

Related Shares

More News
7 Aug 2020 20:11

IN BRIEF: Court Order Sanctions Arsenal's Cello Acquisition

IN BRIEF: Court Order Sanctions Arsenal's Cello Acquisition

4 Aug 2020 09:05

IN BRIEF: Cello Health Gets Shareholder Approval For Arsenal Takeover

IN BRIEF: Cello Health Gets Shareholder Approval For Arsenal Takeover

1 Jul 2020 12:10

Arsenal Capital makes £179m offer for Cello Health

(Sharecast News) - Cello Health said on Wednesday it had agreed to a takeover from private venture company Arsenal Capital Partners, valuing the compa...

13 May 2020 16:18

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

8 Apr 2020 12:53

Wednesday broker round-up

(Sharecast News) - Travis Perkins: JP Morgan downgrades to underweight with a target price of 920p.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.